
|Articles|November 7, 2012
Avedro, EyeGate Pharma to enter agreement
EyeGate Pharma’s broad iontophoresis patent portfolio for corneal collagen cross-linking will be held as exclusive license by Avedro Inc. Delivery approach provides potential additional benefits to current formulation.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
3
AAO 2025: A study of retinal vasculitis events with intravitreal agents
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5


















































.png)


